CASP3 and non-small cell lung carcinoma: Consistent with these results, treatment with BIX activated effector caspase-3 and poly (ADP-ribose) polymerase (PARP) in EGFR-mutant NSCLC cells but not in EGFR-WT NSCLC cells (Fig. 1b).